|
pan-CAF
|
CD49e
|
Ovarian cancer
| |
[23]
|
|
myCAF
|
α-SMAhighIL-6low; RGS5
|
PDAC; TNBC; bladder cancer
|
Myofibroblast-like; matrix deposition;
|
[14, 56, 58]
|
|
iCAF
|
α-SMAlowIL-6high; PDGFR; CXCL12; Ly6c1high; FBLN1
|
PDAC; TNBC; bladder cancer; ICC
|
Inflammatory infiltration; chemokines and cytokines secretion; tumor-promoting
|
[14, 56,57,58,59]
|
|
apCAF
|
MHC-II gene; CD74
|
PDAC; TNBC; ICC
|
Antigen presenting; immunomodulation
|
[57,58,59]
|
|
vCAF
|
MCAM; IL-6
|
ICC
|
Response to hypoxia; mesenchymal cell proliferation
|
[59]
|
|
mCAF
|
POSTN; COL5A1
|
ECM; collagen fibril organization
|
|
EMT-like CAF
|
KRT19
|
Epithelium-like
|
|
vCAF
|
Nidogen-2
|
Breast cancer
|
Vascular development; angiogenesis
|
[60]
|
|
mCAF
|
Fibulin-1; PDGFRα
|
ECM and EMT
|
|
developmental CAF
|
SCRG1
|
Differentiation of cells; development and morphogenesis of tissues
|
|
CAF-A
|
MMP2; DCN; COL1A2
|
Colorectal cancer
|
ECM remodeling
|
[61]
|
|
CAF-B
|
α-SMA; TAGCN; PDGFA
|
Myofibroblast-like
|
|
CAF-cluster2
|
CDK1
|
TNBC
|
Cell cycling
|
[58]
|
|
CAF-cluster3
|
CD53
|
Structural integrity and function of muscle
|
|
CAF-cluster4
|
CRABP1
|
Basement membrane protease associated
|
|
Immunomodulatory CAF
|
IL-6; IL-10; C1QA/B/C; CFB; CXCL1/2/10/12
|
HGSOC
|
Immunomodulation
|
[62]
|
|
CAF-S1/S4
|
CD29; FAP; α-SMA; FSP1; PDGFRβ; CAV1
|
Breast cancer; ovarian cancer
|
Immunomodulation; myCAFs and iCAFs
|
[63,64,65,66]
|
|
CAF-S2/S3
|
Not activated
|
|
CD10+GPR77+ CAFs
|
CD10; GPR77
|
Breast and lung cancer
|
Promoting cancer formation and chemoresistance
|
[54]
|
